英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
59875查看　59875　在百度字典中的解释百度英翻中〔查看〕
59875查看　59875　在Google字典中的解释Google英翻中〔查看〕
59875查看　59875　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
    TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
  • Tevimbra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Tevimbra is used to treat adults with certain types of esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that has spread (metastasized) or cannot be surgically removed
  • BeiGene finally snags FDA approval for PD-1 drug Tevimbra
    Tevimbra secured its initial approval in China in December 2019 for previously treated classical Hodgkin lymphoma Tevimbra isn’t the first PD-1 drug to reach esophageal cancer
  • First-Line Tislelizumab Plus Chemotherapy Approved in ESCC . . .
    The FDA today approved tislelizumab (Tevimbra; BeiGene) plus chemotherapy for the first-line treatment of patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose
  • TEVIMBRA® (tislelizumab-jsgr) for Esophageal Squamous Cell . . .
    Globally, esophageal cancer (EC) is the ninth most diagnosed cancer and the sixth most common cause of cancer-related death 1 There are two primary subtypes of EC, each with distinct clinical features: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) 1 ESCC is a multifactorial disease, with risks that include lifestyle factors, such as tobacco and alcohol use
  • FDA Approves Tevimbra for Advanced Esophageal Cancer at . . .
    BeiGene’s Tevimbra (tislelizumab-jsgr) recently received FDA approval for use in combination with platinum-containing chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 proteins Esophageal squamous cell carcinoma is a subtype of esophageal cancer that originates in the thin, flat cells lining the
  • label - accessdata. fda. gov
    TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor (1 1) Gastric Cancer
  • FDA Approves Tislelizumab for Unresectable or Metastatic ESCC
    The FDA approved tislelizumab alone for patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy not including a PD-1 PD-L1 inhibitor The FDA approved tislelizumab-jsgr (Tevimbra) for treating esophageal squamous cell carcinoma (ESCC) after prior
  • Oncology Drug Reference Sheet: Tislelizumab-Jsgr - ons. org
    Tislelizumab-jsgr (Tevimbra®) is a programmed cell death protein-1 (PD-1) blocking antibody approved in the United States in 2024 for the treatment of certain esophageal and gastric cancers It is administered via IV and works by enhancing the immune system’s ability to target cancer cells
  • FDA Approves Tevimbra Plus Chemotherapy For Some With . . .
    The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1





中文字典-英文字典  2005-2009